Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib

HENDERSON, Nev.--(BUSINESS WIRE)--Feb. 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news